Quick answer: latest quarter results, by ticker or company name

Reported Q: Q2 2025 Rev YoY: +224.4% EPS YoY: +226.3% Move: +0.54%

WuXi XDC Cayman Inc

2268.HK

HKD65.30 0.54%

Exchange HKSE Sector Healthcare Industry Medical Diagnostics Research

Q2 2025

Published: Jun 30, 2025

Company Status Snapshot

Fast view of the latest quarter outcome for 2268.HK

Reported

Report Date

Jun 30, 2025

Quarter Q2 2025

Revenue

1.35B

YoY: +224.4%

EPS

0.28

YoY: +226.3%

Market Move

+0.54%

Previous quarter: Q1 2025

Follow this company to get upcoming quarter alerts automatically.

Earnings Highlights

Revenue of $1.35B up 224.4% year-over-year
EPS of $0.28 increased by 226.3% from previous year
Gross margin of 36.1%
Net income of 372.85M
"N/A" - N/A

2268.HK

Company 2268.HK

Period Q2 2025

Currency CNY

Report Type Quarterly Earnings

Generated Feb 11, 2026

Executive Summary

WuXi XDC Cayman Inc reported a standout QQ2 2025 quarter with notable top-line acceleration and meaningful margin expansion. Revenue for the quarter stood at 1,350,434,500 CNY, up 224.39% year-over-year and 100.00% quarter-over-quarter, accompanied by a gross profit of 487,623,500 CNY and a gross margin of 36.11%. EBITDA reached 418,057,000 CNY, while net income was 372,850,500 CNY, yielding a net margin of 27.61% and an EPS of 0.31 (diluted 0.28). These results reflect stronger demand for the company’s contract research, development and manufacturing organization (CDMO) capabilities, particularly in antibody drug conjugates and related bioconjugates, and improved operating leverage as scale increases.

Key Performance Indicators

Revenue

Increasing

1.35B

QoQ: 100.00% | YoY: 224.39%

Gross Profit

Increasing

487.62M

36.11% margin

QoQ: 100.00% | YoY: 264.35%

Operating Income

Increasing

383.46M

QoQ: 100.00% | YoY: 298.29%

Net Income

Increasing

372.85M

QoQ: 100.00% | YoY: 205.47%

EPS

Increasing

0.31

QoQ: 100.00% | YoY: 226.32%

Revenue Trend

Margin Analysis

Financial Highlights

Revenue: 1,350,434,500 CNY in QQ2 2025; YoY growth 224.39% and QoQ growth 100.00%. Gross Profit: 487,623,500 CNY; Gross Margin: 36.11%. Operating Income: 383,464,500 CNY; Operating Margin: 28.40%. EBITDA: 418,057,000 CNY; EBITDA Margin: 30.96%. Net Income: 372,850,500 CNY; Net Margin: 27.61%. EPS: 0.31; Diluted EPS: 0.28. D&A: 34,592,500 CNY. R&D: 24,741,500 CNY; SG&A: 79,417,500 CNY (incl. SG&A and selling, general & administrative). Current Ratio: 2.20; Quick Ratio: 2.14; Cash Ratio: 0.31. Debt Ratio: 9.78%; Debt-to-Equity: 14.0%; Total Debt-to-Capitalization: 12.2%. Receivables Turnover: 1.49x; Inventory Turnover: 9.47x; CCC: 12.88 days. Cash per Share: 2.93 CNY. Price-to-Book: 6.67x; Price-to-Sales: 18.38x; P/E: 16.64x. CFO per Share: 0.46; Free Cash Flow per Share: -0.0446. Revenue mix and margins imply improving scale with disciplined cost control, though free cash flow remains negative driven by capital and working-capital needs.

Income Statement

Metric	Value	YoY Change	QoQ Change
Revenue	1.35B	224.39%	100.00%
Gross Profit	487.62M	264.35%	100.00%
Operating Income	383.46M	298.29%	100.00%
Net Income	372.85M	205.47%	100.00%
EPS	0.31	226.32%	100.00%

Key Financial Ratios

Gross Profit Margin

Fair

36.10%

Gross profit margin is moderate, room for improvement in cost management

Operating Profit Margin

Excellent

28.40%

Operating margin is exceptional, indicating strong pricing power and operational efficiency

Net Profit Margin

Excellent

27.60%

Net profit margin is exceptional, indicating strong pricing power and operational efficiency

Return on Assets

Fair

7.02%

Return on assets is acceptable but below top-tier companies

Return on Equity

Fair

10.00%

Return on equity is acceptable but below top-tier companies

Current Ratio

Healthy

2.20

Current ratio shows adequate liquidity to meet short-term obligations

Debt to Equity

Conservative

0.14

Debt-to-equity shows conservative leverage and low financial risk

P/E Ratio

Fair Value

16.64x

P/E ratio in line with market averages

Price to Book

High Premium

6.67x

Very high premium suggests asset-light business model or lofty expectations

Historical Earnings Comparison

Period	Revenue ($M)	EPS ($)	YoY Growth	Report
Q2 2025	1,350.43	0.28	+224.4%	View
Q1 2025	1,350.43	0.28	+138.9%	View
Q2 2024	832.60	0.19	+64.6%	View
Q1 2024	832.60	0.19	+70.8%	View

WuXi XDC Cayman Inc (2268.HK) Q2 2025 Earnings Report

Company Status Snapshot

Earnings Highlights

Executive Summary

Key Performance Indicators

Revenue Trend

Margin Analysis

Financial Highlights

Income Statement

Key Financial Ratios

Management Insights Available for Members

Peer Comparison Available for Members

Investment Outlook & SWOT Available for Members

Historical Earnings Comparison

More 2268.HK Quarterly Reports

2268.HK

2268.HK

2268.HK

Related Financial Data

Sector Analysis: Healthcare

2268.HK Full Profile

2268.HK Financial Statements

Earnings Calendar